Hypertension and the heart

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 10, Issue 3, 2006, Pages 198-202

  Mancia, Giuseppe ^a,b,c   Scopelliti, Francesco ^a   Grassi, Guido ^a,b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Cardiopulmonary reflex; Hypertension; Left ventricular hypertrophy

Indexed keywords

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HYPERTENSION; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; HEART; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS;

EID: 33747117972     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253206291315     Document Type: Conference Paper

References (22)

1. Levy D, Anderson KM, Savage D, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factor. The Framingham Heart Study. Ann Intern Med. 1988;108:7-13.
2. Grassi G, Giannattasio C, Seravalle G, Cattaneo BM, Cleroux J, Mancia G. Cardiogenic reflexes and left ventricular hypertrophy. Eur Heart J. 1990;11(Suppl G):95-99.
3. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
4. Grassi G, Seravalle G, Mancia G. Left ventricular hypertrophy and sympathetic activity. Adv Exp Med Biol. 1997;432:173-179.
5. Zanchetti A, Mancia G. Cardiovascular reflexes and hypertension. Hypertension. 1991;18(Suppl III):13-21.
6. Grassi G, Giannattasio C, Cleroux J, et al. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension. 1998;12:227-237.
7. Mancia G, Carugo S, Grassi G, et al, for the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39:744-749.
8. Frolik ED. Risk mechanisms in hypertensive heart disease. Hypertension. 1999;34:782-789.
9. Diamond JA, Phillips RA. Left ventricular hypertrophy, congestive heart failure and coronary flow reserve abnormalities in hypertension. In: Oparil S, Weber MA (eds). Hypertension. Philadelphia, PA: Elsevier Saunders; 2005:250-280.
10. Lorrel BH, Carabello BA. Left ventricular hypertrophy. Pathogenesis, detection and prognosis. Circulation. 2000;102:470-479.
11. Mancia G, Gamba PL, Omboni S, et al. Ambulatory blood pressure monitoring. J Hypertens. 1996;14(Suppl):61-66.
12. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385-1392.
13. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710-714.
14. Jennings GL, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansson L, Birkenhager WH, eds. Handbook of Hypertension, Vol. 18: Assessment of Hypertensive Organ Damage. Amsterdam: Elsevier; 1997:184-229.
15. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
16. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
17. Mathew J, Sleight P, Lonn E, Belanger AJ, Kannel WB; for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
18. Okin PM, Devereux RB, Jern S, et al; for the LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349.
19. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356.
20. Dahlof B, Zanchetti A, Diez J, et al; for the REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855-1864.
21. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997;95:1464-1470.
22. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110:552-557.